Literature DB >> 28944318

Intereye Agreement of Retinopathy of Prematurity from Image Evaluation in the Telemedicine Approaches to Evaluating of Acute-Phase ROP (e-ROP) Study.

Gui-Shuang Ying1, Wei Pan1, Graham E Quinn2, Ebenezer Daniel1, Michael X Repka3, Agnieshka Baumritter2.   

Abstract

PURPOSE: To determine the symmetry on retinal image grading of fellow eyes for retinopathy of prematurity (ROP) features (stage, zone and plus disease) and severity, to provide the basis for the within subject comparison for ROP trials.
DESIGN: Secondary analyses of data from the Telemedicine Approaches to Evaluating of Acute-Phase ROP (e-ROP) Study.
SUBJECTS: Infants with birth weight less than 1251g.
METHODS: Infants underwent serial retinal imaging sessions in both eyes by certified imagers starting at 32-weeks postmenstrual age (PMA). Two trained non-physician readers graded each eye independently for ROP features in a 5 retinal-image set from each session. Discrepancies were adjudicated by a reading center supervisor. Readers were masked to all eye examination results, previous gradings of both eyes, current grading of the fellow eye, and demographic data. MAIN OUTCOME MEASURES: The inter-eye agreement assessed using percent exact agreement and weighted kappa (Kw ) for stage, zone, plus, referral-warranted ROP (RW-ROP, defined as presence of stage 3 or above, plus disease, or zone I ROP), and severity of ROP.
RESULTS: Among 3918 image sessions in 1235 infants, the percent agreement (Kw ) between paired eyes was 75.3% (0.65) for stage of ROP, 82.3% (0.68) for zone of ROP, 78.7% (0.51) for plus disease, 84.7% (0.56) for RW-ROP, and 72.7% (0.63) for severity of ROP. Similar inter-eye agreements were found when considering ROP features at the first image session, at the last image session, at any image session. Based on image evaluations from all sessions, 412 (33.4%) infants had ROP stage 3 or above, 148 (12.0%) had zone I ROP, 70 (5.7%) had plus disease, and 419 (33.9%) had RW-ROP in one or both eyes; symmetrical findings were present in 71.4% for ROP stage 3 or above, 56.8% for zone I ROP, 50.0% for plus disease, and 73.7% for RW-ROP.
CONCLUSIONS: Masked image evaluations by trained readers showed good inter-eye agreement in ROP characteristics, consistent with the high inter-eye agreement in ROP from clinical examinations by ophthalmologists in other studies. These data confirm that acute ROP is typically symmetrical and supports within subject comparison in ROP trials.

Entities:  

Year:  2017        PMID: 28944318      PMCID: PMC5607452          DOI: 10.1016/j.oret.2016.12.005

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  23 in total

Review 1.  The International Classification of Retinopathy of Prematurity revisited.

Authors: 
Journal:  Arch Ophthalmol       Date:  2005-07

2.  Screening examination of premature infants for retinopathy of prematurity.

Authors: 
Journal:  Pediatrics       Date:  2006-02       Impact factor: 7.124

Review 3.  Retinopathy of prematurity.

Authors:  Ann Hellström; Lois E H Smith; Olaf Dammann
Journal:  Lancet       Date:  2013-06-17       Impact factor: 79.321

4.  Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies.

Authors:  James D Reynolds; Velma Dobson; Graham E Quinn; Alistair R Fielder; Earl A Palmer; Richard A Saunders; Robert J Hardy; Dale L Phelps; John D Baker; Michael T Trese; David Schaffer; Betty Tung
Journal:  Arch Ophthalmol       Date:  2002-11

Review 5.  Role of tele-medicine in retinopathy of prematurity screening in rural outreach centers in India - a report of 20,214 imaging sessions in the KIDROP program.

Authors:  Anand Vinekar; Chaitra Jayadev; Shwetha Mangalesh; Bhujang Shetty; Dharmapuri Vidyasagar
Journal:  Semin Fetal Neonatal Med       Date:  2015-06-17       Impact factor: 3.926

6.  Neonatologists' practices and experiences in arranging retinopathy of prematurity screening services.

Authors:  Alex R Kemper; David K Wallace
Journal:  Pediatrics       Date:  2007-09       Impact factor: 7.124

7.  Telemedicine approach to screening for severe retinopathy of prematurity: a pilot study.

Authors:  Anna L Ells; Jonathan M Holmes; William F Astle; Geoff Williams; David A Leske; Michael Fielden; Brad Uphill; Penny Jennett; Marilynne Hebert
Journal:  Ophthalmology       Date:  2003-11       Impact factor: 12.079

8.  Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): four-years of screening with telemedicine.

Authors:  Natalia Fijalkowski; Luo Luo Zheng; Michael T Henderson; Matthew B Wallenstein; Theodore Leng; Darius M Moshfeghi
Journal:  Curr Eye Res       Date:  2013-01-18       Impact factor: 2.424

9.  Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity.

Authors:  Graham E Quinn; Gui-shuang Ying; Ebenezer Daniel; P Lloyd Hildebrand; Anna Ells; Agnieshka Baumritter; Alex R Kemper; Eleanor B Schron; Kelly Wade
Journal:  JAMA Ophthalmol       Date:  2014-10       Impact factor: 7.389

Review 10.  Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010.

Authors:  Hannah Blencowe; Joy E Lawn; Thomas Vazquez; Alistair Fielder; Clare Gilbert
Journal:  Pediatr Res       Date:  2013-12       Impact factor: 3.756

View more
  3 in total

1.  Extending Hui-Walter framework to correlated outcomes with application to diagnosis tests of an eye disease among premature infants.

Authors:  Yu-Lun Liu; Gui-Shuang Ying; Graham E Quinn; Xiao-Hua Zhou; Yong Chen
Journal:  Stat Med       Date:  2021-12-03       Impact factor: 2.497

2.  Progression from preplus to plus disease in the Telemedicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) Study: incidence, timing, and predictors.

Authors:  Qianqian Ellie Cheng; Graham E Quinn; Ebenezer Daniel; Agnieshka Baumritter; Eli Smith; Gui-Shuang Ying
Journal:  J AAPOS       Date:  2020-11-16       Impact factor: 1.220

3.  Assessing Intereye Symmetry and Its Implications for Study Design.

Authors:  Maureen G Maguire
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.